The founders nailed the timing for the company's public debut in 2021, but the short-term tradeoffs made then are now biting investors. A fair valuation on the other side of $1 per share leaves only one option.

Shield is likely to become the second blood test approved to screen for colon cancer, but reimbursement coverage might disappoint investors and complicate commercial launch.